-
Developing a tailored vaccine is part of the company’s standard procedure for new variants
BioNTech SE said Monday that it had started working in a vaccine adapted to omicron, the worrying new variant of the coronavirus detected in South Africa, although it was not yet clear whether it would have to rework its established covid-19 trigger.
Developing a tailored vaccine it is part of the company’s standard procedure for new variants, BioNTech, which makes vaccines together with Pfizer, said in a statement.
“The first steps to develop a potential new vaccine overlap with the research needed to assess whether a new vaccine will be needed, “he added.
Related news
The Omicron variant carries a global risk very high overloads, warned the WHO on Monday as that more countries reported cases, prompting border closures.
BioNTech had said on Friday that it expects more laboratory data for the next two weeks to help determine if there is a need for a specific Omicron vaccine. Rival Moderna has said it was working on a redesign of its covid-19 vaccine for future booster injections.
Reference-www.elperiodico.com